• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Ranbaxy Laboratories Ltd - Articles and news items

Lixiana

Merger between Daiichi Sankyo subsidiary Ranbaxy and Sun Pharma completed

Industry news / 25 March 2015 / Victoria White

Daiichi Sankyo have announced that the Sun Pharma and Ranbaxy merger process has been completed…

Daiichi Sankyo logo

Announcement regarding merger between Sun Pharma and Daiichi Sankyo’s subsidiary Ranbaxy and resulting change in subsidiary

Industry news / 11 April 2014 / Daiichi Sankyo

As announced in a release dated April 7, 2014, pursuant to a merger transaction, whereby Daiichi Sankyo Company, Limited has agreed with Sun Pharmaceutical Industries Ltd…

Daiichi Sankyo logo

Daiichi Sankyo agrees to vote its shares in Ranbaxy in favor of Sun Pharma’s Acquisition

Industry news / 7 April 2014 / Daiichi Sankyo

Pursuant to the merger transaction announced between Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Ltd. announces that it has agreed to vote its shares in Ranbaxy in favor of Sun Pharma’s acquisition of 100%…

Daiichi Sankyo logo

Subpoena for Ranbaxy’s Toansa Plant

Industry news / 7 April 2014 / Daiichi Sankyo

Attached is the statement of Ranbaxy Laboratories, a subsidiary of Daiichi Sankyo Company, Limited, which was issued on April 7th, 2014…

Ranbaxy Laboratories Logo

Ranbaxy suspends shipments of active pharmaceutical ingredients (APIs) produced at Indian plants

Industry news, News / 25 February 2014 / Daiichi Sankyo Company

Daiichi Sankyo has announced that its consolidated subsidiary, Ranbaxy Laboratories, will temporarily suspended shipments of active pharmaceutical ingredients (APIs) produced at its Toansa and Dewas plants in India.

Daiichi Sankyo logo

Update on Regarding the Import Alert on Ranbaxy’s Toansa Plant

Industry news / 24 January 2014 / Daiichi Sankyo Company

Ranbaxy Laboratories Limited announced that the US FDA notified the company that it is prohibited from manufacturing and distributing active pharmaceutical ingredients from its facility in Toansa, India, for FDA-regulated drug products…

Daiichi Sankyo logo

Regarding the import alert on Ranbaxy’s Toansa Plant

Industry news / 24 January 2014 / Daiichi Sankyo

Daiichi Sankyo Company Ltd. announced that the US Food and Drug Administration has issued an import alert on January 23 on Active Pharmaceutical Ingredients…

Daiichi Sankyo logo

Statement regarding FDA inspection of Ranbaxy’s Toansa plant

Industry news / 14 January 2014 / Daiichi Sankyo Co., Ltd

Ranbaxy received the form 483 with certain observations as a result of the recent US FDA inspection at its API plant at Toansa, Punjab, India…

Ranbaxy building

FDA imposes import ban on Ranbaxy’s Mohali plant

Industry news, News / 24 September 2013 / Daiichi Sankyo Company, Limited

Ranbaxy Laboratories has received communication from the FDA about an Import Alert imposed on its Mohali, India, plant following an inspection in late 2012…

Ranbaxy Laboratories Logo

Ranbaxy announces conclusion of previously disclosed investigation by U.S Department of Justice

Industry news, News / 13 May 2013 / DAIICHI SANKYO COMPANY, LIMITED

“Today’s announcement marks the resolution of this past issue…”

Indian flag

Sun shines on Indian generics manufacturers

Industry news, News / 3 April 2013 / GlobalData

India is becoming a key market for generic medicines…

Daiichi Sankyo logo

Daiichi Sankyo and Ranbaxy to leverage synergies in Thailand

Industry news, News / 16 January 2013 / Daiichi Sankyo

Daiichi Sankyo and Ranbaxy announced their intention to integrate their business operations in Thailand…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +